This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

In contrast to albinism where melanocytes are present but unable to produce pigment, vitiligo is characterised by the loss of melanocytes, from affected areas.


  • although histological and histochemical evidence point out that melanocytes are lost from the white patches, Tobin et al managed to culture some melanocytes from the white patches in people with long standing disease
  • in some instances melanocytes appear to survive in hair follicles within the patches (1)

The aetiology of this condition is unknown, both environmental and genetic factors are believed to play an important role (1). Hypotheses which explain the pathogenesis of vtiligo include:

  • autoimmune damage to melanocytes
  • autocytotoxic - the autodestruction of melanocytes by toxic intermediates of melanin synthesis
  • neurogenic dysfunction
  • oxidative stress
  • viral
  • melanocyte detachment (5)

Of these, autoimmune hypothesis appears most likely, with anti-melanocyte antibodies being found in some patients, and the apparent association of vitiligo with autoimmune disorders including diabetes mellitus, pernicious anaemia, Addison's disease and autoimmune thyroiditis (5).

Many patients also show a positive family history. Around 20-30% of patients has first or second degree relatives with vitiligo (5)


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.